Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi‐agent chemotherapy

导出原文传递

翻译打印收藏纠错

作者： Walewski Jan ^[1] ; Hellmann Andrzej ^[2] ; Siritanaratkul Noppadol ^[3] ; Ozsan Guner Hayri ^[4] ; Ozcan Muhit ^[5] ; Chuncharunee Suporn ^[6] ; Goh Ai Sim ^[7] ; Jurczak Wojciech ^[8] ; Koren Jan ^[9] ; Paszkiewicz‐Kozik Ewa ^[10] ; Wang Bingxia ^[11] ; Singh Shalini ; Huebner Dirk ; Engert Andreas ; Tresckow Bastian

作者单位： Department of Internal MedicineUniversity Hospital CologneCologne,Germany ^[1] Department of Lymphoid MalignancyMaria Sklodowska‐Curie Institute – Oncology CentreWarszawa,Poland ^[2] Department of HaematologyAnkara University School of MedicineAnkara,Turkey ^[3] Oncology CentreRamathibodi HospitalBangkok,Thailand ^[4] Department of MedicineHospital Pulau PinangPulau Pinang,Malaysia ^[5] Department of HaematologyJagiellonian UniversityKraków,Poland ^[6] Department of MedicineSiriraj HospitalBangkok,Thailand ^[7] Department of HaematologyDokuz Eylul UniversityIzmir,Turkey ^[8] Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company ^[9] Department of HaematologyCharles UniversityPrague,Czech Republic ^[10] Department of HaematologyMedical University of GdańskGdańsk,Poland ^[11]

关键词 Hodgkin lymphoma relapsed/refractory novel anti‐tumour agents brentuximab vedotin phase IV

发布时间 2020-06-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交